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The Effect of Treatment of Cystic Fibrosis Pulmonary
Exacerbations on Airways and Systemic Inflammation
Damian G. Downey, MD,1,2 Simon Brockbank, PhD,1 S. Lorraine Martin, PhD,2
Madeleine Ennis, PhD,1 and J. Stuart Elborn, MD1,2*
Summary. Background: Chronic infection in cystic fibrosis (CF) and airway inflammation leads
to progressive lung injury. Neutrophils are considered to be responsible for the onset and
promotion of the inflammatory response within the CF lung. The relationship between infection
and inflammation is complex but circulating inflammatory markers may not truly reflect the local
inflammatory response in the lung. The aims of this study were to investigate the change of
inflammatory biomarkers and cells within sputum and blood before and after intravenous
antibiotics for a pulmonary exacerbation of CF. Methods: Assays included neutrophil elastase
(NE) and complex, interleukin-8 (IL-8) and soluble intercellular adhesion molecule-1 (sICAM-1),
fas ligand (FAS-L), and TNFr-1. Analysis of sputum cell differential and absolute cell counts and
immunocytochemistry (CD11b and CD95) on sputum and isolated blood neutrophils were carried
out. Results: There were no significant differences in absolute or differential sputum cell counts or
sputumsolmeasurements following antibiotics. Therewasa significant increase in the percentage
of blood neutrophilswithminimal CD11bstaining, 28 (4.1)meanpercentage (SEM) versus 41 (2.9)
and a decrease in the percentage showingmaximal staining 30 (0.5) versus 15 (2.5). There was a
significant increase in the percentage of blood neutrophils without CD95 staining, 43 (5.4) mean
percentage versus 52 (5.1). Conclusion: These data suggest amodifiable systemic response to IV
antibiotics but a local sustained inflammatory response in the lung. Pediatr Pulmonol. 2007;
42:729–735.  2007 Wiley-Liss, Inc.
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BACKGROUND
Chronic infection in cystic fibrosis (CF) and associated
intermittent infective exacerbations with airway inflam-
mation lead to progressive lung injury.1 Neutrophils are
considered responsible for the onset and promotion of the
inflammatory response in the CF lung.2 The mechanisms
leading to this response remain largely unknown. It
remains unclear whether infection precedes inflammation
or vice versa. The relationship between infection and
inflammation is complex. The host inflammatory response
is not necessarily proportional to the burden of pathogens
in the airways but the pathogens may trigger these
responses.3 Lung inflammation is hard to quantify,
therefore the systemic host inflammatory response is used
as a marker of disease activity. It has been shown that
inflammatory markers, C-reactive protein (CRP) and
neutrophil elastase complex (NEC) fall significantly after
a pulmonary exacerbation has been treated with intra-
venous (IV) antibiotics4 but circulating markers may not
truly reflect the local inflammatory response in the lung.
Resolution of this inflammatory process is not well
understood. However, it is recognized that neutrophil
apoptosis is an important mechanism for neutrophil
removal at sites of lung inflammation, therefore limiting
the potential proteolytic damage to the lung.5
The aims of this study were to investigate the
modulation of soluble inflammatory factors within
sputum, blood inflammatory markers, differential sputum
cell counts, and neutrophil surface receptors before and
after administration of IV antibiotics for a pulmonary
exacerbation of CF. The differences in sputum sampling
techniques were examined by comparing expectorated,
physiotherapy, and induced sputum samples. We hypo-
thesized that markers of inflammationwould decrease and
apoptosis increase following treatment.
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MATERIALS AND METHODS
Sixteen patients with a pulmonary exacerbation of CF
were admitted to the study. The diagnosis of CF had
previously been established by genetic analysis and/or
sweat testing. All patients had a sweat chloride concen-
tration >60 mmol/L and one or two disease causing
mutations. A pulmonary exacerbation was defined as an
increase in pulmonary symptoms i.e., cough, sputum
production, and shortness of breath and a10% decrease
in FEV1 compared to baseline. Patients taking cortico-
steroids were excluded from the study. Patients were
admitted to the Regional Adult Cystic Fibrosis Centre
in the Belfast City Hospital (BCH) for 2 weeks of IV
antibiotic therapy. Before the start of IV treatment (V1)
and following completion of 14 days of treatment (V2), a
number of parameters were assessed. This study was
approved by the local ethics committee. Informed written
consent was obtained in all cases.
Spirometry (FEV1 and FVC) was carried out according
to the American Thoracic Society guidelines.6 Patients
were then asked to provide a spontaneously expectorated
sputum sample (E). This was followed by a session of
physiotherapy based on the active cycle of breathing;7
sputum samples were collected during and after this
procedure and labeled (P). Finally sputum was induced
using a methodology derived from Fahy and colleagues8
using 3% hypertonic saline and a Devilbiss 20001
ultrasonic nebulizer (I). The three sputum samples col-
lected were transferred immediately to the laboratory.
Sputum plugs, free of salivary contamination were
selected using plastic forceps (to a weight of 300 mg)
and placed in a sterile tube. The methodology used to
process the sputum plugs was derived from Cai and
co-workers.9 The remaining sputum was centrifuged at
30,000 g for 1 hr at 48C. The sol was aspirated, protease
inhibitors added,10 and frozen at 708C for future
analysis.
Free neutrophil elastase (NE) activity was measured in
induced sputum sol by a colorimetric microtitre plate
assay,11 using the elastase substrate Suc-Ala-Ala-Pro-Val-
pNA (Bachem,Walden, Essex). The detection limit for the
assay was 30 ng/ml. Intra-assay and inter-assay coef-
ficients of variation were 4.5 and 8.2%, respectively.
Soluble neutrophil elastase complex (sNEC) was
quantified in induced sputum sol by an enzyme-linked
immunosorbent assay (ELISA).12 The lower detection
limit for the assaywas 5 ng/ml. Intra-assay and inter-assay
coefficients of variation were 4.6 and 7.2%, respectively.
The assay for plasma NEC (pNEC) was as above but with
the following changes: the antibody pair used was sheep
anti-human NE IgG and a peroxidase-conjugated sheep
anti-human alpha-1-antitrypsin IgG (The Binding Site,
Birmingham, England) and the plasma samples were
diluted in PBS containing 0.05% (v/v) Tween-20.
Interleukin-8 (IL-8), soluble intercellular adhesion
molecule-1 (sICAM-1), and soluble Fas ligand (sFAS-L)
were measured using commercially available ELISA kits
(R&D Systems, Abingham, Oxon, UK). The detection
limits for the assays were 10 pg/ml, 0.35 ng/ml, and
3.6 pg/ml respectively.
Soluble TNF receptor-1 (sTNFr-1) was measured in
sputum sol by sandwich ELISA.13 The assay had a
detection limit of 0.5 ng/ml. Intra-assay and inter-assay
coefficients of variation were 5.8 and 8.4%, respectively.
Blood samples included full blood count (FBC) and
CRP, both measured by routine methods in NHS labora-
tories. Ear lobe blood gas analysis was carried out as
follows. Transvesin1 cream was applied to one ear lobe
for 10 min and then wiped off. Using a 21-gauge needle,
the ear lobe was gently pricked to produce a small drop of
blood. This blood was drawn into a heparinized glass
capillary tube (Instrumentation Laboratory, Lexington,
MA) via capillary action, by gently touching the drop of
blood with one end of the tube. The capillary tube was
immediately transferred to a blood gas analyzer Synthesis
10 (Instrumentation Laboratory). Neutrophils were iso-
lated from peripheral blood using a method adapted from
Firestein et al.14
Total cell counts and cell viability using the trypan blue
exclusion test. Slides were prepared of blood and sputum
neutrophil using the glass coverslip method as previously
prescribed.15 Differential cell counts were carried out on
the slides using a Speedy-Diff (Clin-tech Ltd., Guildford,
UK) kit according to the manufacturer’s instructions. The
remaining slides were wrapped in aluminium foil and
stored at 708C for future analysis.
Cell surface receptor analysis was carried out as
follows. Slides were removed from the 708C freezer
and left to thaw, still wrapped in aluminium foil, for 2 hr at
room temperature. The slides were unwrapped and placed
in a bath of 1% paraformaldehyde (PFA) for 5 min.
Immunocytochemistry was performed using the DAKO
APAAP Kit, System 40, K670 (Dako, Cambridgeshire,
UK). The primary antibodies used were CD11b and CD
95 (Dako). The cells were then assessed for fast red
staining (using a phase contrast microscope) i.e., absent
(), minimal (þ), moderate (þþ), or maximal (þþþ)
staining and counted (Fig. 1) as per previously
described.16,17 All slides were assessed by one blinded
observer.
Prism softwarewas employed for the statistical analysis
of this study. Differences before and after antibiotics were
assessed using the paired Student’s t-test. Differences in
cell counts between sputum methods were assessed using
the Kruskal–Wallis test. Analyses on sol samples, CRP,
pNEC, and total cell counts were carried out on log-
transformed data. The transformations normalized the
distributions. A P-value using two-tailed testing of<0.05
was considered statistically significant.
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RESULTS
Patient Demographics
The mean age of the patients was 25 years, range (15–
37). Sputum culture isolated Pseudomonas aeruginosa
(Pa) alone from four patients, Burkholderia cenocepacia
(Bc) from five patients, Pa and Bc from three patients,
Pa and S aureus, Bc and H influenzae, H influenzae, and
S Pneumoniae from one patient each. Antibiotic choice
varied between patients, depending on microbiological
susceptibility testing and clinical response. Initial anti-
biotic choices (two to three antibiotics per patient) includ-
ed tobramycin (n¼ 14), ceftazidime (n¼ 10), aztreonam
(n¼ 3), meropenem (n¼ 2), tazobactam (n¼ 2), genta-
micin (n¼ 2), flucloxacillin (n¼ 1), and cefotaxime
(n¼ 1).
Lung Function Tests and Blood Gases
Lung function tests (FEV1 and FVC) were compared at
the start (V1) and end (V2) of IV antibiotics. Following
completion of treatment, therewas a significant increase in
lung function. FEV1 1.88 (1.4–2.4) L mean (95% CI)
versus 2.36 (1.7–3.0) L, P¼ 0.002, FVC 2.67 (2.2–3.1) L
versus 2.97 (2.5–3.5) L, P¼ 0.01. Capillary blood gas
analysis of pH, partial pressure of oxygen (pO2), partial
pressure of carbon dioxide (pCO2), and oxygen saturation
(O2 sat) showed no significant change after antibiotics
(data not shown). There was a weak positive correlation
between lung function and capillary oxygenation (pO2)
before antibiotics (V1), FEV1 r
2¼ 0.3, P¼ 0.04 and FVC
r2¼ 0.3, P¼ 0.04, but this relationship was lost after
completion of antibiotics (V2).
Blood Count and CRP
There was a small but statistically significant change
in haemoglobin, 14.05 (0.31) g/dl mean (SEM) versus
13.62 (0.37) g/dl, P¼ 0.04. There was a statistically




There was no significant difference in sputum cell
viability between V1 and V2 for each method of sputum
collection, (E) 80 (3.0)% versus 72 (5.1), P¼ 0.14, (P)
82 (3.1) versus 73 (4.0), P¼ 0.11, (I) 81 (2.8) versus 76
(3.7), P¼ 0.31. There were no significant differences in
mean cell viability between each of the three sputum
methodologies within V1 or V2.
Total Cell Counts
Sputum total cell counts (log-transformed data) were
reduced after IV antibiotics and reached statistical signi-
ficance in expectorated sputum. (E) 1.0(0.13) 106 cells/
g sputum versus 0.48 (0.18), P¼ 0.04, (P) 1.09 (0.16)
versus 0.91 (0.15), P¼ 0.4 and (I) 1.14 (0.14) versus 0.93
(0.13), P¼ 0.50 (Fig. 2). Differences in total cell counts
between the three sputum methodologies were assessed
with no significant differences observed within V1,
P¼ 0.71, or V2, P¼ 0.14.
Percentage Cell Counts
Percentage neutrophils, macrophages, eosinophils,
lymphocytes, and squamous cells were calculated. There
was a non-significant decrease in (E) neutrophils,
Fig. 1. The above immunocytochemistry slide shows sputum
cells stained with primary antibody CD11b.
Fig. 2. Total cell counts X106 cells/gram of sputumSEM (log-
transformed data) for each of the sputum sampling methods, E
(expectorated sample), P (physiotherapy-induced sample), and I
(induced sputum sample) before (V1) and after (V2) IV antibiotics
(n¼16).
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94 (1.5)% versus 82 (6.8)%, P¼ 0.33 and increase in
squamous cells 3 (0.8) versus 14 (6.3), P¼ 0.23 following
antibiotics.
The differences in percentage cell type (neutrophils,
macrophages, lymphocytes, eosinophils and squamous
cells) between the three sputum methodologies at any
one time point was assessed. There was a significantly
greater percentage of squamous cells in expectorated
sputum, 3 (0.8) compared with (P), 1 (0.3) and (I), 1 (0.8),
P¼ 0.03 at V1.
Absolute Cell Counts
There were non-significant reductions in absolute
neutrophil counts following antibiotics for each of the
sputum methodologies, (E) 19 (5) 106 cells/g sputum
versus 6 (4) P¼ 0.18, (P) 25 (6) versus 12 (4) P¼ 0.17,
(I) 26 (6) versus 13 (5) P¼ 0.06. Comparing the cells
between the three sputum methodologies at any one
time point only the squamous cells differed significantly
(E) 0.3 (0.07) 106 cells/g sputum compared to (P)
0.16 (0.06) 106 cells/g sputum and (I) 0.06 (0.02)
106 cells/g sputum, (P¼ 0.03) at V1.
Sputum Sol Measurements
Sputum sol mediators (NE, sNEC, IL-8, sICAM-1,
sFAS-L, and sTNFr-1) did not differ significantly after
2 weeks of antibiotic treatment (Table 1).
Immunocytchemistry
There was no significant change in levels of CD11b
expression on sputum neutrophils following completion
of IV antibiotic treatment. In contrast, there was a sig-
nificant increase in the percentage of blood neutrophils
exhibiting minimal CD11b staining and a significant
decrease in the percentage showing maximal staining
(Table 2). There was no significant change in levels of
CD95 expression on sputum neutrophils following
completion of IV antibiotic treatment. However, a
significant increase in the percentage of blood neutrophils
without CD95 staining was found and a trend for a
decrease in the percentage showing maximal staining
(Table 3).
DISCUSSION
A 2-week course of IV antibiotics for a pulmonary
exacerbation of CF resulted in a clinical improvement
which was reflected in a significant increase in lung
function (FEV1 and FVC). We investigated the effects of
this treatment on a selection of inflammatory biomarkers,
differential cell counts, and neutrophil surface receptors.
The differences in sputum recovery methods were also
highlighted which has important practical implications.
Previous studies have examined differential cell counts
in BAL and induced sputum in patients with CF and
induced sputum has been used where expectoration was
unsuccessful within the same study.19 This assumes the
composition of expectorated and induced sputum to be
similar. There have been no studies to determine that
differing methods of obtaining sputum in patients with CF
yield comparable total and differential cell counts. In this
study, therewas a trend for a greater number of cells in the
physiotherapy and induced sputum per gram of sputum
compared to the expectorated sputum, but this did not
reach statistical significance. This difference may be due
to improved cell recovery rather than true cell number
increase. The expectorated samples tended to be more
tenacious resulting in increased numbers of cells mixed
with cellular debris being removed at the filtration stage.
Regardless of the technique involved cell viability was
similar in all groups.
Percentage cell counts were similar between groups but
there was a significantly higher percentage of squamous
cells in the expectorated compared to the induced sputum.
Physiotherapy and induced sputum groups had higher
absolute neutrophil and macrophage counts compared to
expectorated sputum but this did not reach statistical
significance. A possible explanation of cellular differ-
ences is that induced sputum may originate more distal in
the airway than an expectorated sample. This area requires
further investigation as changes in cellular composition
between differing sputum samples suggest that induced
TABLE 1— Comparison of Inflammatory and Apoptotic Markers in Induced Sputum Sol
Before (Visit 1-V1) and After (Visit 2-V2) IV Antibiotics
V1 V2 P-value
NE (ug/ml) 53.42 (30.5) 11.24 (3.06) 0.83
sNEC (ug/ml) 4.61 (1.99) 1.41 (0.63) 0.33
IL-8 (ng/ml) 51.75 (5.74) 57.95 (12.6) 0.89
sICAM-1 (ng/ml) 13.72 (2.16) 14.32 (2.98) 0.39
sFAS-L (ng/ml) 0.36 (0.1) 0.18 (0.01) 0.11
sTNFr-1 (ug/ml) 4.41 (0.86) 2.72 (0.48) 0.12
Data (n¼ 16) are given as mean (SEM). P-values were calculated on log-transformed data.
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and expectorated samples should not be used interchange-
ably in studies.
It has been demonstrated that total cell counts in
induced sputum are reproducible (within week) in stable
patients with CF.20 Furthermore Watt et al. observed
similar sputum total cell counts irrespective of the
colonized pathogen (including Bc and Pa).21 Our inves-
tigation showed a reduction in sputum total cell counts
following treatment for each of the sputum method-
ologies. This only reached statistical significance in the
expectorated group, possibly due to the number of patients
in the study. Percentage differential cell counts were
similar following antibiotics; however a decrease was
observed in expectorated sputum neutrophils with an
increase in squamous cells. Difficulty in expectoration of
sputum following antibiotics could account for this
change.
A recent study has shown the reproducibility of sputum
inflammatory markers in stable patients with CF.22 In our
study, there was a non-statistically significant reduction in
sputum sol biomarkers (NE and sNEC) following treat-
ment. There was also a non-significant trend for reduction
in WCC, PMN, and pNEC. CRP, which is a non-specific
marker of inflammation, fell significantly after treat-
ment. However, in a study by Hendry et al. significant
reductions were observed in WCC, CRP, and pNEC
following antibiotics.18
IL-8, a powerful neutrophil chemoattractant, did not
change in our study. A recent investigation did show a
reduction in IL-8 following IVantibiotics.23 Furthermore
Ordonez et al. demonstrated a reduction in NE and IL-8
following IV antibiotics.24 This was in a larger cohort of
younger patients who were given IV antibiotics for up to
34 days.
ICAM-1 contributes to neutrophil influx into the airway
lumen and its expression is increased on inflamed endo-
thelium by proinflammatory cytokines.25 Although the
pathophysiological function of sICAM-1 remains to be
specified, a shift of its lung concentration is likely to reflect
increased cellular ICAM-1 expression.26 Following treat-
ment with antibiotics there was no change in sICAM-1 in
sputum sol despite a slight reduction in neutrophil counts,
which may in part represent an ICAM-1-independent
neutrophil recruitment pathway in CF lungs. However,
Salva et al. showed that sICAM-1 levels in CF sputum
were lower in those who were acutely ill compared to
stable patients, with no change following IVantibiotics.27
The binding of sICAM-1 to CD11/CD18 receptor on
neutrophils in acutely ill patients may explain this.27
Expression of sputum neutrophil CD11b, an important
ligand of ICAM-1 and a marker of neutrophil activation,
did not significantly change following treatment. This
suggests that unchanged expression of CD11b and
sICAM-1 levels could reflect continued airway neutrophil
activation. In comparison, blood neutrophil CD11b
expression was reduced. This study in part supports
our hypothesis that systemic inflammation is reduced
following IV antibiotics, but there is a persistent inflam-
matory response in the airway. Thus, despite clinical
improvement there is likely ongoing airway damage.
TABLE 2— Percentage of Sputum and Blood Neutrophils With Absent (), Minimal (þ), Moderate (þþ), or Maximal (þþþ)
CD11b Staining Before (V1) and After (V2) IV Antibiotics
Sputum neutrophils Blood neutrophils
V1 V2 P-value V1 V2 P-value
 21 (9.1) 14 (4.8) 0.27 5 (1.5) 9 (4.2) 1.00
þ 17 (6.6) 17 (5.1) 0.95 28 (4.1) 41 (2.9) 0.03
þþ 30 (6.9) 28 (4.6) 0.81 36 (5.5) 36 (3.8) 1.00
þþþ 31 (10.5) 38 (8.6) 0.51 30 (5.0) 15 (2.5) 0.008
Data (n¼ 16) are given as mean (SEM).
TABLE 3— Percentage of Sputum and Blood Neutrophils With Either Absent (), Minimal (þ), Moderate (þþ), or Maximal
(þþþ) CD95 Staining Before (V1) and After (V2) IV Antibiotics
Sputum neutrophils Blood neutrophils
V1 V2 P-value V1 V2 P-value
 15 (4.3) 16 (5.0) 0.73 43 (5.4) 52 (5.1) 0.007
þ 58 (2.6) 46 (5.9) 0.20 38 (1.8) 36 (2.9) 0.32
þþ 25 (3.4) 31 (6.0) 0.25 15 (3.8) 11 (2.5) 0.10
þþþ 3 (1.2) 7 (2.3) 0.15 4 (1.8) 1 (0.5) 0.06
Data (n¼ 16) are given as mean(SEM).
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These effects should be further investigated with serial
measurements of these markers in patients remote from a
pulmonary infection.
We hypothesized that neutrophil apoptosis would be
increased following treatment of a pulmonary exacerba-
tion in order to help resolve the inflammatory process.
CD95 or Fas is an important part of the cellular pathway
regulating the induction of apoptosis. Its expression on
sputum neutrophils did not alter with treatment but its
expression on blood neutrophils decreased following
antibiotics. sFAS-L is an inducer of apoptosis. Following
treatment of pulmonary exacerbations, sFAS-L levels fell
by half but did not reach statistical significance. This
suggests that this pathway of apoptosis is more active
at the beginning rather than the end of a pulmonary
exacerbation disproving our hypothesis. But other apop-
totic pathways may be involved. Soluble TNFr-1 was also
reduced following treatment. Occupancy of TNF recep-
tors by TNF-a initiates apoptosis; however prolonged
incubation of neutrophils with TNF-a can reduce
apoptosis.28 The soluble TNF receptor reflects TNF
activation by inhibiting TNF action in vivo; it is therefore
viewed as anti-inflammatory. Therefore within the com-
plex inflammatory milieu in the CF lung, it is difficult to
determinewhether it functions as an inducer of neutrophil
apoptosis or not. Measuring serial TNF-a levels, correlat-
ing with soluble receptors, and quantifying TNFr-1 with
immunocytochemistry could help resolve this.
This study is the first to use immunocytochemistry of
both sputum and blood neutrophils alongside soluble
markers of neutrophil activation and apoptosis, to
determine the effects of treatment on pulmonary exacer-
bations. The inflammatory process is complicated, although
the surface and soluble markers measured in this study do
not reflect the complete process, they do provide valuable
information. Further work is required to explore these
methods and ultimately improve our understanding of
inflammation and its resolution within CF airways.
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